Operational Pressure Builds: Layoffs, Supply Risk, and Regulatory Friction

Jana Chisholm
2 hours ago
4 min read

From workforce reductions to manufacturing bottlenecks and regulatory divergence, structural pressures are reshaping how pharma operates

Executive Highlights

More than 22,000 pharma jobs were cut in 2025, reflecting a broad industry reset tied to patent cliffs and cost discipline.
Merck & Co. is reducing headcount following a sharp decline in Gardasil demand, particularly in China.
CSL Behring is facing supply constraints for Hemgenix, highlighting scalability challenges in gene therapy.
Europe continues to lag the U.S. in approvals by ~4–8 months, with longer delays to patient access influencing launch strategy.

Introduction

While innovation across biopharma continues to accelerate, a parallel reality is unfolding behind the scenes: increasing operational pressure.

Companies are simultaneously managing:

Patent expirations across major franchises
Manufacturing complexity for advanced therapies
Regional regulatory divergence
And the need to maintain cost discipline

Recent developments across vaccines, gene therapy, and workforce restructuring illustrate how these pressures are converging—and how companies are adapting.

Merck Responds to Vaccine Demand Decline

Merck & Co. has begun workforce reductions, cutting 147 employees plus an additional 7 roles, as it adjusts to declining demand for its HPV vaccine Gardasil.

Financial context:

2025 Gardasil sales: $5.2 billion
Year-over-year decline: 39%
Q4 China sales: effectively zero

The decline is largely attributed to a sharp drop in demand in China, which had been a major growth driver for the franchise.

This shift highlights a broader reality: even established blockbuster products are exposed to regional demand variability, policy changes, and shifting public health priorities.

Gene Therapy: Commercial Potential Meets Manufacturing Reality

CSL Behring recently reported a global stockout of Hemgenix, its gene therapy for hemophilia B.

Commercial snapshot:

Patients treated globally: ~75
2025 revenue: $57 million

Despite strong clinical outcomes, Hemgenix underscores the gap between scientific innovation and commercial scalability.

Key constraints:

Small-batch, highly specialized manufacturing
Multi-step quality testing and release processes
Dependence on limited production capacity
Long lead times from production to treatment

These constraints continue to slow adoption across gene therapy programs industry-wide.

Workforce Reset: Not Just Cuts, But Strategic Reallocation

Operational pressure is also visible in workforce trends. Across the pharmaceutical sector, more than 22,000 jobs were cut in 2025, driven by:

Patent cliffs impacting major revenue streams
Post-pandemic normalization
Increasing focus on productivity and margins

However, the industry is not simply shrinking — it is strategically reallocating talent.

Where talent is moving away from:

Mature primary care franchises
Slower-growth vaccine segments
Legacy commercial models

Where talent is moving toward:

High-growth therapy areas such as oncology, immunology, and cardiometabolic disease
Advanced modalities including RNA therapeutics, gene therapy, and biologics
Functions tied to data science, AI-driven development, market access, and specialty care commercialization

Real-world examples:

Novo Nordisk reduced approximately 7,500 roles while continuing to expand in obesity and diabetes
Pfizer eliminated roughly 13,000 positions over two years as it reset post-COVID
Meanwhile, Eli Lilly and Novo Nordisk increased combined headcount by more than 36,000 employees between 2021 and 2025, driven by growth in metabolic disease

This divergence reflects a structural shift:

Rather than broad contraction, pharma is reallocating resources toward the areas expected to drive the next decade of growth.

Increasingly, companies are also optimizing revenue per employee, using workforce structure as a lever to improve overall productivity.

Regulatory Timing Is Becoming a Strategic Variable

Differences in approval timelines between the United States and Europe are increasingly influencing global launch strategy.

Across studies, the European Medicines Agency (EMA) typically approves drugs 4 to 8 months later than the U.S. Food and Drug Administration (FDA). In oncology, review timelines alone can differ by 5–7 months, and the gap widens further when accounting for pricing and reimbursement.

In many European markets, patient access can lag approval by an additional year or more, as national health systems negotiate pricing and coverage.

Real-world examples

Alzheimer’s therapies have experienced delayed European decisions compared to the U.S., reflecting more complex safety and evidentiary review processes.
In oncology, FDA approvals can occur in roughly 6 months, while European timelines extend significantly longer due to multi-country coordination.

Obesity and GLP-1s: A Strategic Launch Example

The obesity market provides a clear illustration of how companies are adapting.

Both Novo Nordisk and Eli Lilly have prioritized the U.S. market for their GLP-1 therapies due to:

Faster regulatory pathways
Higher pricing flexibility
Stronger early revenue potential

n contrast, European launches often face:

Pricing negotiations at the national level
Reference pricing pressures across countries
Slower reimbursement decisions

As a result, companies may:

Launch first in the U.S.
Delay or phase European rollout
Or adjust pricing strategies to protect global benchmarks

This dynamic is increasingly important given the projected size of the obesity market, which analysts estimate could reach $100B+ globally over the next decade.

The Convergence of Pressures

These forces are not independent — they reinforce each other.

Declining revenue → drives cost cuts and layoffs
Manufacturing limits → constrain commercial scaling
Regulatory delays → shift investment and launch strategy
Workforce shifts → reshape organizational capabilities

The result is a more complex operating environment where execution risk is rising alongside scientific opportunity.

Outlook: Execution Becomes the Differentiator

Biopharma is entering a phase where success depends not only on innovation, but on operational execution.

Companies must now align:

Scalable manufacturing
Workforce strategy
Regulatory planning
Commercial infrastructure

Those that succeed will convert innovation into sustained growth.

Those that do not may find that even strong pipelines are not enough to overcome operational constraints.

Eyes On Pharma Blog